MedTrace Logo

Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)

NCT05817604 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-05-10

No results posted yet for this study

Summary

Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer

Conditions

  • Kidney Neoplasm
  • Renal Cancer
  • Inoperable Disease
  • SBRT
  • SABR

Interventions

RADIATION

SBRT

Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme. Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme.

Sponsors & Collaborators

  • Consorci Sanitari de Terrassa

    lead OTHER

Principal Investigators

  • Manuel Galdeano-Rubio, MD · Consorci Sanitari de Terrassa

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2026-05-01
Completion
2028-05-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817604 on ClinicalTrials.gov